

The Inchstone Project

Community Update

March 25, 2024









What is The Inchstone Project?

Mission: To make <u>clinical development more inclusive</u> by developing a battery of FDA-approved Clinical Outcome Assessments within 5 years that are:

- psychometrically sound,
- → sensitive to meaningful change, and
- → fit-for-purpose for severe DEEs

Assure every person, regardless of the severity of their disease, can have even their smallest achievements, or inchstones, counted.

<u>Agenda</u>

- Recap of Inchstone Vision and Approach
- Highlights and Importance of Results from DEE Parents Speak Survey
 - Overview of Parent Speak survey
 - Overview of Parent Priorities and Areas of Impairment
 - Analysis of Qualitative Data from Parent Speak survey
 - Quality of Life Scores
 - Developmental Quotients
 - Awareness and Responsiveness
 - Cortical Visual Impairment
 - Sample PAG Dashboard
- Open discussion/ Q&A
- Continuing Ways to engage
 - Upcoming Focus groups
 - FDA Listening session
 - Expanded clinical assessments

The Inchstone Project Team



Anne Berg



Mary Wojnaroski



Natasha Ludwig Jenny Downs





Becky Hommer













Sophie Haywood Kelly Muzyczka JayEtta Hecker Gunes Sevinc

Gabi Conecker Chere Chapman

3 Phases of The Inchstone Project

Phase 1 Foundation

2022

- Confirming the need ~2A pilot
- Building the team and governance
- Developing a plan
- · Community engagement

_ THE INCHSTONE PROJECT

Phase 2 Design

2023-2024

- · Community engagement
- · Confirming caregiver priorities
- Studying priority tools to adapt
- Develop an Inchstone COA Battery
- Design of validation plans

_THE INCHSTONE PROJECT

Phase 3 Validation

2025-2026

- Test/Retest
- Psychometric evaluation
- Piloting
- Release of Inchstone COA

THE INCHSTONE PROJECT

Working Hypotheses of The Inchstone Project

Need/challenge

More sensitive and validated outcome measures are essential for progress in precision medicine (PM)

Developing assessment tools disease by disease is unsustainable. Doing this together gets us all closer to PM faster.

Inchstone R&D

DEEs and severe NDDs have many common characteristics and similar priorities for improvement

Development of an Inchstone COA Battery validated for use across the DEEs/severe NDDS will


- → improve meaningful inclusion of DEEs in trials
- → improve efficiency & effectiveness of trials


Participants and Characteristics of DEE Parent Speak Study

Enrollment criteria for Priorities Survey


- Initial
 - At least 1-year old
 - Have very severe communication challenges.
 - Unable to walk or unable to feed self (including g-tube dependent)
 - •Have one or more of: seizures, developmental delay, intellectual disability, autism
- After Sept 13, 2023 and the LGS meeting
 - At least 1-year old
 - Have very severe communication challenges.
 - Unable to walk or unable to feed self (including g-tube dependent)
 - •Have one or more of: seizures, developmental delay, intellectual disability, autism

DEE Parents Speak Survey Overview






Muscle and Tone Disorders



Severe to Profound Impairment: Compass Points of Function



Mobility – 2 years and older

100


80

60

40

20







Light touch

Supported both


hands






Of 52% requiring a wheelchair/stroller in the home

Walker/rollator



Communication



Aides and Assistive Devices

Therapeutic stroller **74%**



AFOs **62%**



Medical bed/crib



Rollator - Walker **24%**



Arm-wrist brace 14%



Medical lift or hoist 18%






Other Devices

AAC 39%



Other breathing aides 10%



CPAP device

7 %



Cough assist device

11%



Noise cancellation head phones

14%



Suction device

24 %




Activities enjoyed

Perecnt


Passive activities were indicated more often for the most impaired participants






Priorities by: Disease Group & Level of Severity

Communication is top priority across disease groups




Priorities change based on disease severity



Communication as a priority is consistent between gene groups and is the top priority regardless of the number of domains with severe impairments

Gross motor and fine motor are bigger priorities as number of severe domains increases, while behavior decreases as a priority as number of severe impacts increases

Number of domains with profound impairment by gene/epilepsy groups



Analysis of Qualitative Data from DEE-Wide Survey

specific	build improve just one aspect of your child's condition of those listed above, what would you choose? We are ally interested in the domains we just asked you about above but there is room for additional possibilities at the
	his section.
	arms and legs and trunk - Gross motor skills
	fingers and wrists - Fine motor skills
	standing others - receptive communication
Expres	sing self to others - expressive communication
O Eating	safely without risk of choking
O Feedin	g self independently, without help from another
O Vision	
O Alertn	ess, responsiveness, and attention
O Reason	ning and problem solving
O Proble	ms falling or staying asleep or waking up in the morning
O Sleepii	ness during the day, trouble staying awake
O Behav	ioral and emotional self-regulation
	cting with and responding to others - social engagement
	blems - constipation, gut dysmotility
	nent disorder
O Dysau	
O Pain	
te PI	that would be the smallest improvement or step forward in this area that would be important to you or your child it is a few to be objective as possible. What would someone who does not know your child that well be able to observe? The would this small improvement be important to you/your child?

Q44. If you could improve one other aspect of your child's condition, what would you choose? We are specifically interested in the domains we just asked you shout above but there is room for additional possibilities at the end of this section.

For example - Expressive Communication

Q45 - What would you see?

It is difficult to understand her basic needs

Q46 - What is better?

Is she in actual pain, does she have gas, or is it positional when she seems unable to engage in activities?

Q47 - Why? It would aid in intervention, if we understood the source, we could offer either medicine, a shift in position, or some other intervention


Total number of wishes = 807

Wish Name	All	ASMs	Autism	LGS	ASXL1	ASXL3	FOXG1	SCN2A	SCN8A	SHANK	XXXOT
Expressive Comms	211	137	83	40	14	15	18	17	24	43	80
Gross Motor Skills	102	79	14	25	12	3	14	11	11	7	44
Receptive Comms	73	34	39	10	4	5	2	3	11	23	25
Behavior	59	33	37	4	3	8	1	6	8	14	19
Sleep Problems	46	30	16	15	1	4	3	3	6	7	22
GI Problems	45	30	18	8	5	4	4	5	4	10	13
Feeding Independently	43	26	13	7	4	6	6	1	3	5	18
Fine Motor Skills	35	27	10	9	3	0	5	6	4	4	13
Social Engagement	35	25	17	6	2	3	1	1	9	6	13
Eating Safely	28	17	12	4	1	0	2	2	4	8	11
Alertness	24	16	9	4	2	0	2	3	1	1	15
Vision	22	15	3	4	0	1	4	4	2	2	9
Reasoning	16	9	6	1	1	1	0	0	3	4	7
Movement	12	8	2	1	0	0	6	0	1	2	3
Reduce Pain	11	10	2	3	1	2	2	0	3	0	3
Sleepiness	10	10	2	5	0	0	0	0	1	1	8
Dysautonomias	7	5	1	3	1	0	0	1	1	0	4
TOTAL	269	175	99	51	18	18	24	21	32	50	106

Code	Description	Number	Percentage
EC19	Basic communication of needs/wants	56	26.29
EC30	Express pain/hurt/discomfort	38	17.84
EC62	Communicate – aided – not specified	35	16.43
EC45	Communicate body– limbs (hand gestures, pointing, waving, kicking, moving feet, push button)	32	15.02
EC21	Communication - not specified	30	14.08
EC60	Communicate – words – not specified	21	9.86
EC20	Express feelings	20	9.39
EC32	Communicate Yes/No	19	8.92
EC41	Consistency of communication	13	6.10
EC57	Communicate – words – single	12	5.63
EC49	Communicate – vocalisation (squealing, moaning, yelling, grunting, laughing, crying, babbling)	10	4.69


Quality of Life Scores Across Disease Groups

Quality of Life Scores by Burden of Impairment





Quality of Life Score by Domains and Impairments















28

Quality of Life Score by Domains and Impairments




Development Quotient Across Disease Groups

Developmental Profile-4

Caregiver rating of development in 5 areas:


- Cognitive
- Communication
- Physical
- Social-Emotional
- Adaptive Behavior

Developmental Quotients (DQ) - Overall




DQ by Gene Group

DEVELOPMENTAL QUOTIENTS BY GENE GROUPS




DQ by Number of Profoundly Impacted Domains

DQ BY BURDEN OF IMPAIRMENT



DP4 Raw Scores




What percent of kids scored at the floor (0) for each of the DP4 categories?

Awareness and Responsiveness

What does it look like when your child is having a good day?





Targeting alertness, awareness, responsiveness may be important and meaningful to measure for those who are severely impaired

Caregiver Responsivity Inventory (CRI)

(Ludwig et al. adapted from Wolff et al, 2019)

Domain	Average
Auditory (0-4)	2.22
Visual (0-5)	3.63
Motor (0-6)	4.33
Vocal (0-3)	1.96
Communication (0-2)	0.67
Arousal (0-3)	2.21
Total (0-23)	14.84 (no ceiling/ floor)

Auditory

 Does your relative move their head or eyes towards the location of a sound? Yes.

Visual

- Is your relative able to recognize two objects that are presented to them? Yes.
- Is your relative able to follow with their eyes? Yes.

Motor

Does your relative move their hand to grasp an object and hold it? Yes.

Vocal

Does your relative produce sounds? Yes.

Communication


Does your child cry or smile? Yes.

Arousal

 Does your relative usually keep their eyes open independently during school or therapies? Yes.

Distribution of scores

Distribution of CRS-P Total Scores
Gene Group and Number Severly Impacted Domains




Takeaway:

Gene Groups

ASXL1
ASXL3
FOXG1
SCN2A
SCN8A
SHANK
XXXOT

Responsivity decreases with more severe impairment.

Correlation with DP4 scores




Takeaways:

Responsivity increases with more cognitive ability.


The CRI shows far more variability in scores than the DP-4 for those below a 12 month-level.

Cortical Visual Impairment


Cortical/Cerebral Visual Impairment




CVI by Gene Group




CVI diagnosis differs by age at time of survey



CVI diagnosis increases with number of impairments



Ability to Tell if My Child Can See Something by Diagnosis Status



The Importance of Vision in Communication

- •Non-ocular impairment in visual processing "Software" issue
- Color
- Movement
- •Fields
- Latency
- Complexity
- Environment
- Faces
- •Light
- Novelty
- Reaching



VINELAND-3 – early communication items

- Looks at caregiver who is gesturing to get attention
- •Responds appropriately to 3+ facial expressions


CSBS


- •Does your child smile or laugh while looking at you?
- •When you look at and point to a toy across the room, does your child look at it?

mCHAT


- •When you smile at your child, does he or she smile back at you...?
- •Does your child look you in the eye when you are talking to him or her, playing with him/her....?

Factors Affecting My Child's Vision by Diagnosis Status





Novel Parent-Report Measure of CVI Severity Based on the CVI Range: Scores by CVI Diagnosis Status



These initial findings are promising and exciting, but there is more work to be done to validate the measure

Groups based on parent-report of CVI diagnosis

Community Profiles of Disease Groups with >20 Participants

SCN8A

Inchstone Results

This report provides both a broad overview of our SCN8A sample, as well as key highlights from the survey results.




Total 32





Average Age 11.4





Sex 59% Female














LGS

Inchstone Results

This report provides both a broad overview of our LGS sample, as well as key highlights from the survey results.



Total


51




Average Age



Sex 51% Female







92.2% use a wheelchair



0% are completely independent for the toilet




65% using 4+ ASMs





50% have diagnosed CVI



19% use an alternative communication device







THE INCHSTONE PROJECT

Q&A

Discussion

Continuing Opportunities to Help Advance Work of The Inchstone Project

Focus Groups

Entirely virtual, led by one of our DEE researchers

We will have 5 separate sessions

Cognition

Quality of Life

Vision

Awareness and Responsiveness

Priorities and Impacts

If you participated in the DEE Parents Speak Survey and indicated you were open to joining the post-survey focus groups, we will be in touch soon with additional details

This isn't another survey, but a chance for your feedback on the process and a key part in understanding the limitations and room for improvement in current and developing instruments

Proposing FDA Listening Session for DEEs and Severe NDDs

- Listening Session: 90 min informal, non-regulatory meetings between FDA staff and patients
- Participants: Caregivers, advocates, community representatives, and FDA staff
- Purpose: Share patient experiences, perspectives, and needs related to their health or a disease
- Benefits: Helps FDA connect with under-represented communities and understand patient needs

Opportunity to participate in expanded clinical assessments

Kennedy Krieger - Contact Natasha at: LudwigResearch@kennedykrieger.org
or

Nationwide - Contact Mary at: Mary.Wojnaroski@nationwidechildrens.org



The Inchstone Project is Recruiting for a New In-Person Study

The Inchstone Project is recruiting for a new in-person research study to explore better ways to measure abilities in individuals with severe neurodevelopmental disabilities.

Children and adults with 1) severe to profound intellectual disability (ID) or global developmental delay (GDD) and 2) either severe motor impairments (i.e., unable to walk independently) and/or a gastronomy tube may be eligible for participation in this study.



Interested families are encouraged to contact the study team to learn more and to complete a short screening survey to check eligibility at: LudwigResearch@kennedykrieger.org

This study has been approved by the Johns Hopkins School of Medicine (IRB IRB00382308)

Principal Investigator: Natasha Ludwig, PhD



Confirmed 2024 Industry Partners



Jazz Pharmaceuticals.













































THE INCHSTONE PROJECT

Thank you!

Reach out anytime with questions or ideas: gabi@d-de.org